Back to Search Start Over

Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network

Authors :
Alessio Signori
Johannes Lorscheider
Sandra Vukusic
Maria Trojano
Pietro Iaffaldano
Jan Hillert
Robert Hyde
Fabio Pellegrini
Melinda Magyari
Nils Koch-Henriksen
Per Soelberg Sørensen
Tim Spelman
Anneke van der Walt
Dana Horakova
Eva Havrdova
Marc Girard
Sara Eichau
Francois Grand'Maison
Oliver Gerlach
Murat Terzi
Serkan Ozakbas
Olga Skibina
Vincent Van Pesch
Maria Jose Sa
Julie Prevost
Raed Alroughani
Pamela A McCombe
Riadh Gouider
Saloua Mrabet
Tamara Castillo-Trivino
Chao Zhu
Koen de Gans
José Luis Sánchez-Menoyo
Bassem Yamout
Samia Khoury
Maria Pia Sormani
Tomas Kalincik
Helmut Butzkueven
Source :
Journal of neurology, neurosurgery, and psychiatry. 94(1)
Publication Year :
2022

Abstract

BackgroundOver the decades, several natural history studies on patients with primary (PPMS) or secondary progressive multiple sclerosis (SPMS) were reported from international registries. In PPMS, a consistent heterogeneity on long-term disability trajectories was demonstrated. The aim of this study was to identify subgroups of patients with SPMS with similar longitudinal trajectories of disability over time.MethodsAll patients with MS collected within Big MS registries who received an SPMS diagnosis from physicians (cohort 1) or satisfied the Lorscheider criteria (cohort 2) were considered. Longitudinal Expanded Disability Status Scale (EDSS) scores were modelled by a latent class growth analysis (LCGA), using a non-linear function of time from the first EDSS visit in the range 3–4.ResultsA total of 3613 patients with SPMS were included in the cohort 1. LCGA detected three different subgroups of patients with a mild (n=1297; 35.9%), a moderate (n=1936; 53.6%) and a severe (n=380; 10.5%) disability trajectory. Median time to EDSS 6 was 12.1, 5.0 and 1.7 years, for the three groups, respectively; the probability to reach EDSS 6 at 8 years was 14.4%, 78.4% and 98.3%, respectively. Similar results were found among 7613 patients satisfying the Lorscheider criteria.ConclusionsContrary to previous interpretations, patients with SPMS progress at greatly different rates. Our identification of distinct trajectories can guide better patient selection in future phase 3 SPMS clinical trials. Additionally, distinct trajectories could reflect heterogeneous pathological mechanisms of progression.

Details

ISSN :
1468330X
Volume :
94
Issue :
1
Database :
OpenAIRE
Journal :
Journal of neurology, neurosurgery, and psychiatry
Accession number :
edsair.doi.dedup.....5520ef9681321e89dd60c4277050931f